Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersOperating ExpensesOperating IncomeProfit After TaxResearch & DevelopmentSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Denali Therapeutics (DNLI) Revenue (2018 - 2023)

Denali Therapeutics has reported Revenue over the past 6 years, most recently at $1.3 million for Q3 2023.

  • Quarterly Revenue fell 64.4% to $1.3 million in Q3 2023 from the year-ago period, while the trailing twelve-month figure was $1.3 million through Jun 2024, down 99.63% year-over-year, with the annual reading at $330.5 million for FY2023, 204.74% up from the prior year.
  • Revenue was $1.3 million for Q3 2023 at Denali Therapeutics, down from $294.1 million in the prior quarter.
  • Over five years, Revenue peaked at $316.9 million in Q4 2020 and troughed at $1000.0 in Q1 2021.
  • The 5-year median for Revenue is $9.4 million (2020), against an average of $43.4 million.
  • Year-over-year, Revenue tumbled 99.97% in 2021 and then skyrocketed 4214000.0% in 2022.
  • A 5-year view of Revenue shows it stood at $4.7 million in 2019, then surged by 6683.13% to $316.9 million in 2020, then tumbled by 96.05% to $12.5 million in 2021, then fell by 20.09% to $10.0 million in 2022, then plummeted by 87.33% to $1.3 million in 2023.
  • Per Business Quant, the three most recent readings for DNLI's Revenue are $1.3 million (Q3 2023), $294.1 million (Q2 2023), and $35.1 million (Q1 2023).